XML 14 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 2 - Summary of Significant Accounting Policies (Details) (USD $)
 3 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
DePuy Mitek, Inc., Medtronic Xomed, Soylu Medikal San ve Dis Tic Ltd., Rivex Pharma, and Takeda/Nycomed/Biomeks [Member]
Customer Concentration Risk [Member]
Accounts Receivable [Member]
Dec. 31, 2012
DePuy Mitek, Inc., Medtronic Xomed, Soylu Medikal San ve Dis Tic Ltd., Rivex Pharma, and Takeda/Nycomed/Biomeks [Member]
Customer Concentration Risk [Member]
Accounts Receivable [Member]
Dec. 31, 2013
Computer Hardware and Software [Member]
Minimum [Member]
Dec. 31, 2013
Computer Hardware and Software [Member]
Maximum [Member]
Dec. 31, 2013
Furniture and Fixtures [Member]
Minimum [Member]
Dec. 31, 2013
Furniture and Fixtures [Member]
Maximum [Member]
Dec. 31, 2013
Leasehold Improvements [Member]
Minimum [Member]
Dec. 31, 2013
Leasehold Improvements [Member]
Maximum [Member]
Dec. 31, 2013
General and Administrative Expense [Member]
Dec. 31, 2012
General and Administrative Expense [Member]
Dec. 31, 2011
General and Administrative Expense [Member]
Dec. 31, 2013
Anika Therapeutics S.r.l. [Member]
Dec. 31, 2013
Trade Names [Member]
Dec. 31, 2012
In-process research & development [Member]
Dec. 13, 2013
Fair Value, Inputs, Level 1 [Member]
Dec. 13, 2012
Fair Value, Inputs, Level 1 [Member]
Dec. 31, 2013
Minimum [Member]
Computer Software, Intangible Asset [Member]
Dec. 31, 2013
Maximum [Member]
Computer Software, Intangible Asset [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]                                            
Foreign Currency Transaction Gain (Loss), before Tax   $ 259,275 $ 200,452 $ (623,093)                                    
Cash and Cash Equivalents, Fair Value Disclosure                                     34,266,501 34,264,268    
Long-term Debt 9,600,000   9,600,000                                      
Allowance for Doubtful Accounts Receivable, Current 337,459 593,023 337,459                                      
Allowance for Doubtful Accounts Receivable, Write-offs   0 135,353 2,047                                    
Provision for Doubtful Accounts   238,071 135,353 331,528                 238,071 138,339 306,520              
Concentration Risk, Percentage         67.00% 78.00%                                
Inventory, Net 8,283,472 10,996,785 8,283,472                                      
Inventory Adjustments 1,161,805 758,106 1,161,805                                      
Property, Plant and Equipment, Useful Life             3 years 5 years 5 years 7 years 6 months 24 years                    
Business Acquisition, Purchase Price Allocation, Goodwill, as Percentage of Total Purchase Price                               100.00%            
Restructuring Costs and Asset Impairment Charges 2,500,000 (160,559) 1,604,256                             1,200,000        
Finite-Lived Intangible Asset, Useful Life                                 10 years       2 years 10 years
Impairment of Long-Lived Assets to be Disposed of $ 300,000                                          
Number of Reportable Segments   1